Chemical attenuation of pilus function and assembly in Gram-negative bacteria

Current Opinion in Microbiology

Volumn 16, Issue 1, 2013, Pages 85-92

  Lo, Alvin W H ^a,b   Moonens, Kristof ^a,b   Remaut, Han ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; COTRIMOXAZOLE; PEPTIDOMIMETIC AGENT;

BACTERIUM PILUS; BINDING AFFINITY; BINDING SITE; BIOFILM; CELL ADHESION; CELL INVASION; FIMBRIA; GRAM NEGATIVE BACTERIUM; MICROBIAL ATTENUATION; NONHUMAN; PRECIPITATION; PROTEOBACTERIA; REVIEW; RHIZOBIUM RADIOBACTER; TYPE IV SECRETION SYSTEM; UROPATHOGENIC ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; FIMBRIAE, BACTERIAL; GRAM-NEGATIVE BACTERIA; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 84875810597     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.02.003     Document Type: Review

References (58)

1. Fronzes R., Remaut H., Waksman G. Architectures and biogenesis of non-flagellar protein appendages in Gram-negative bacteria. EMBO J 2008, 27:2271-2280.
2. Barnhart M.M., Chapman M.R. Curli biogenesis and function. Annu Rev Microbiol 2006, 60:131-147.
3. Craig L., Pique M.E., Tainer J.A. Type IV pilus structure and bacterial pathogenicity. Nat Rev Microbiol 2004, 2:363-378.
4. Dodson K.W., Pinkner J.S., Rose T., Magnusson G., Hultgren S.J., Waksman G. Structural basis of the interaction of the pyelonephritic E. coli adhesin to its human kidney receptor. Cell 2001, 105:733-743.
5. Langermann S., Palaszynski S., Barnhart M., Auguste G., Pinkner J.S., Burlein J., Barren P., Koenig S., Leath S., Jones C.H., et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997, 276:607-611.
6. Mulvey M.A., Lopez-Boado Y.S., Wilson C.L., Roth R., Parks W.C., Heuser J., Hultgren S.J. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 1998, 282:1494-1497.
7. Roberts J.A., Marklund B.I., Ilver D., Haslam D., Kaack M.B., Baskin G., Louis M., Mollby R., Winberg J., Normark S. The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc Natl Acad Sci U S A 1994, 91:11889-11893.
8. Cegelski L., Marshall G.R., Eldridge G.R., Hultgren S.J. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008, 6:17-27.
9. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008, 6:e280.
10. Cho I., Yamanishi S., Cox L., Methe B.A., Zavadil J., Li K., Gao Z., Mahana D., Raju K., Teitler I., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012, 488:621-626.
11. Walsh C., Fanning S. Antimicrobial resistance in foodborne pathogens-a cause for concern?. Curr Drug Targets 2008, 9:808-815.
12. Shryock T.R., Richwine A. The interface between veterinary and human antibiotic use. Ann N Y Acad Sci 2010, 1213:92-105.
13. Wizemann T.M., Adamou J.E., Langermann S. Adhesins as targets for vaccine development. Emerg Infect Dis 1999, 5:395-403.
14. Cehovin A., Winterbotham M., Lucidarme J., Borrow R., Tang C.M., Exley R.M., Pelicic V. Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine 2010, 28:4817-4826.
15. Tramont E.C., Boslego J.W. Pilus vaccines. Vaccine 1985, 3:3-10.
16. Hur J., Lee J.H. Comparative evaluation of a vaccine candidate expressing enterotoxigenic Escherichia coli (ETEC) adhesins for colibacillosis with a commercial vaccine using a pig model. Vaccine 2012, 30:3829-3833.
17. Langermann S., Mollby R., Burlein J.E., Palaszynski S.R., Auguste C.G., DeFusco A., Strouse R., Schenerman M.A., Hultgren S.J., Pinkner J.S., et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 2000, 181:774-778.
18. De Greve H., Wyns L., Bouckaert J. Combining sites of bacterial fimbriae. Curr Opin Struct Biol 2007, 17:506-512.
19. Garnett J.A., Martinez-Santos V.I., Saldana Z., Pape T., Hawthorne W., Chan J., Simpson P.J., Cota E., Puente J.L., Giron J.A., et al. Structural insights into the biogenesis and biofilm formation by the Escherichia coli common pilus. Proc Natl Acad Sci U S A 2012, 109:3950-3955.
20. Nuccio S.P., Baumler A.J. Evolution of the chaperone/usher assembly pathway: fimbrial classification goes Greek. Microbiol Mol Biol Rev 2007, 71:551-575.
21. Anderson K.L., Billington J., Pettigrew D., Cota E., Simpson P., Roversi P., Chen H.A., Urvil P., du Merle L., Barlow P.N., et al. An atomic resolution model for assembly, architecture, and function of the Dr adhesins. Mol Cell 2004, 15:647-657.
22. Van Molle I., Joensuu J.J., Buts L., Panjikar S., Kotiaho M., Bouckaert J., Wyns L., Niklander-Teeri V., De Greve H. Chloroplasts assemble the major subunit FaeG of Escherichia coli F4 (K88) fimbriae to strand-swapped dimers. J Mol Biol 2007, 368:791-799.
23. Zavialov A., Zav'yalova G., Korpela T., Zav'yalov V. FGL chaperone-assembled fimbrial polyadhesins: anti-immune armament of Gram-negative bacterial pathogens. FEMS Microbiol Rev 2007, 31:478-514.
24. Hung C.S., Bouckaert J., Hung D., Pinkner J., Widberg C., DeFusco A., Auguste C.G., Strouse R., Langermann S., Waksman G., et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol 2002, 44:903-915.
25. Wellens A., Garofalo C., Nguyen H., Van Gerven N., Slattegard R., Hernalsteens J.P., Wyns L., Oscarson S., De Greve H., Hultgren S., et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS One 2008, 3:e2040.
26. Bouckaert J., Berglund J., Schembri M., De Genst E., Cools L., Wuhrer M., Hung C.S., Pinkner J., Slattegard R., Zavialov A., et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 2005, 55:441-455.
27. Jiang X., Abgottspon D., Kleeb S., Rabbani S., Scharenberg M., Wittwer M., Haug M., Schwardt O., Ernst B. Antiadhesion therapy for urinary tract infections-a balanced PK/PD profile proved to be key for success. J Med Chem 2012, 55:4700-4713.
28. Klein T., Abgottspon D., Wittwer M., Rabbani S., Herold J., Jiang X., Kleeb S., Luthi C., Scharenberg M., Bezencon J., et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 2010, 53:8627-8641.
29. Schwardt O., Rabbani S., Hartmann M., Abgottspon D., Wittwer M., Kleeb S., Zalewski A., Smiesko M., Cutting B., Ernst B. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem 2011, 19:6454-6473.
30. Wellens A., Lahmann M., Touaibia M., Vaucher J., Oscarson S., Roy R., Remaut H., Bouckaert J. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH. Biochemistry 2012, 51:4790-4799.
31. Han Z., Pinkner J.S., Ford B., Obermann R., Nolan W., Wildman S.A., Hobbs D., Ellenberger T., Cusumano C.K., Hultgren S.J., et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 2010, 53:4779-4792.
32. Larsson A., Ohlsson J., Dodson K.W., Hultgren S.J., Nilsson U., Kihlberg J. Quantitative studies of the binding of the class II PapG adhesin from uropathogenic Escherichia coli to oligosaccharides. Bioorg Med Chem 2003, 11:2255-2261.
33. Ohlsson J., Jass J., Uhlin B.E., Kihlberg J., Nilsson U.J. Discovery of potent inhibitors of PapG adhesins from uropathogenic Escherichia coli through synthesis and evaluation of galabiose derivatives. Chembiochem 2002, 3:772-779.
34. Salminen A., Loimaranta V., Joosten J.A., Khan A.S., Hacker J., Pieters R.J., Finne J. Inhibition of P-fimbriated Escherichia coli adhesion by multivalent galabiose derivatives studied by a live-bacteria application of surface plasmon resonance. J Antimicrob Chemother 2007, 60:495-501.
35. Buts L., Bouckaert J., De Genst E., Loris R., Oscarson S., Lahmann M., Messens J., Brosens E., Wyns L., De Greve H. The fimbrial adhesin F17-G of enterotoxigenic Escherichia coli has an immunoglobulin-like lectin domain that binds N-acetylglucosamine. Mol Microbiol 2003, 49:705-715.
36. Le Trong I., Aprikian P., Kidd B.A., Forero-Shelton M., Tchesnokova V., Rajagopal P., Rodriguez V., Interlandi G., Klevit R., Vogel V., et al. Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like beta sheet twisting. Cell 2010, 141:645-655.
37. Moonens K., Bouckaert J., Coddens A., Tran T., Panjikar S., De Kerpel M., Cox E., Remaut H., De Greve H. Structural insight in histo-blood group binding by the F18 fimbrial adhesin FedF. Mol Microbiol 2012, 86:82-95.
38. Coddens A., Diswall M., Angstrom J., Breimer M.E., Goddeeris B., Cox E., Teneberg S. Recognition of blood group ABH type 1 determinants by the FedF adhesin of F18-fimbriated Escherichia coli. J Biol Chem 2009, 284:9713-9726.
39. Cusumano C.K., Pinkner J.S., Han Z., Greene S.E., Ford B.A., Crowley J.R., Henderson J.P., Janetka J.W., Hultgren S.J. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 2011, 3:109ra115.
40. Guiton P.S., Cusumano C.K., Kline K.A., Dodson K.W., Han Z., Janetka J.W., Henderson J.P., Caparon M.G., Hultgren S.J. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob Agents Chemother 2012, 56:4738-4745.
41. Han Z., Pinkner J.S., Ford B., Chorell E., Crowley J.M., Cusumano C.K., Campbell S., Henderson J.P., Hultgren S.J., Janetka J.W. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 2012, 55:3945-3959.
42. Waksman G., Hultgren S.J. Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat Rev Microbiol 2009, 7:765-774.
43. Remaut H., Rose R.J., Hannan T.J., Hultgren S.J., Radford S.E., Ashcroft A.E., Waksman G. Donor-strand exchange in chaperone-assisted pilus assembly proceeds through a concerted beta strand displacement mechanism. Mol Cell 2006, 22:831-842.
44. Phan G., Remaut H., Wang T., Allen W.J., Pirker K.F., Lebedev A., Henderson N.S., Geibel S., Volkan E., Yan J., et al. Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature 2011, 474:49-53.
45. Svensson A., Larsson A., Emtenas H., Hedenstrom M., Fex T., Hultgren S.J., Pinkner J.S., Almqvist F., Kihlberg J. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2001, 2:915-918.
46. Pinkner J.S., Remaut H., Buelens F., Miller E., Aberg V., Pemberton N., Hedenstrom M., Larsson A., Seed P., Waksman G., et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci U S A 2006, 103:17897-17902.
47. Chorell E., Pinkner J.S., Phan G., Edvinsson S., Buelens F., Remaut H., Waksman G., Hultgren S.J., Almqvist F. Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J Med Chem 2011, 53:5690-5695.
48. Nishiyama M., Horst R., Eidam O., Herrmann T., Ignatov O., Vetsch M., Bettendorff P., Jelesarov I., Grutter M.G., Wuthrich K., et al. Structural basis of chaperone-subunit complex recognition by the type 1 pilus assembly platform FimD. EMBO J 2005, 24:2075-2086.
49. Chorell E., Pinkner J.S., Bengtsson C., Banchelin T.S., Edvinsson S., Linusson A., Hultgren S.J., Almqvist F. Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study. Bioorg Med Chem 2012, 20:3128-3142.
50. Chorell E., Bengtsson C., Sainte-Luce Banchelin T., Das P., Uvell H., Sinha A.K., Pinkner J.S., Hultgren S.J., Almqvist F. Synthesis and application of a bromomethyl substituted scaffold to be used for efficient optimization of anti-virulence activity. Eur J Med Chem 2011, 46:1103-1116.
51. Cegelski L., Pinkner J.S., Hammer N.D., Cusumano C.K., Hung C.S., Chorell E., Aberg V., Walker J.N., Seed P.C., Almqvist F., et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 2009, 5:913-919.
52. Blanco L.P., Evans M.L., Smith D.R., Badtke M.P., Chapman M.R. Diversity, biogenesis and function of microbial amyloids. Trends Microbiol 2012, 20:66-73.
53. Horvath I., Weise C.F., Andersson E.K., Chorell E., Sellstedt M., Bengtsson C., Olofsson A., Hultgren S.J., Chapman M., Wolf-Watz M., et al. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation. J Am Chem Soc 2012, 134:3439-3444.
54. Chabre Y.M., Roy R. Recent trends in glycodendrimer syntheses and applications. Curr Top Med Chem 2008, 8:1237-1285.
55. Sunden F., Hakansson L., Ljunggren E., Wullt B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol 2010, 184:179-185.
56. Watts R.E., Tan C.K., Ulett G.C., Carey A.J., Totsika M., Idris A., Paton A.W., Morona R., Paton J.C., Schembri M.A. Escherichia coli 83972 expressing a P fimbriae oligosaccharide receptor mimic impairs adhesion of uropathogenic E. coli. J Infect Dis 2012, 206:1242-1249.
57. Cameron T.A., Zambryski P.C. Disarming bacterial type IV secretion. Chem Biol 2012, 19:934-936.
58. Duncan M.C., Linington R.G., Auerbuch V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob Agents Chemother 2012, 56:5433-5441.